Quantitative Screening of Protein Glycation, Oxidation, and Nitration Adducts by LC-MS/MS: Protein Damage in Diabetes, Uremia, Cirrhosis, and Alzheimer's Disease

Redox Proteomics: From Protein Modifications to Cellular Dysfunction and Diseases

Volumn , Issue , 2006, Pages 681-727

  Thornalley, Paul J ^a  

^a UNIVERSITY OF ESSEX   (United Kingdom)

Author keywords

Glycation adducts in food and beverages; Protein damage in diabetes, uremia, cirrhosis and AD; Protein glycation, oxidation and nitration quantitation

Indexed keywords

EID: 52249110240     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/0471973122.ch22     Document Type: Chapter

References (174)

1. Agalou S., Ahmed N., Babaei-Jadidi R., Dawnay A., Thornalley P.J. (2005). Profound mishandling of protein glycation degradation products in uremia and dialysis. J Am Soc Nephrol 16: 1471-1485.
2. Ahmed M.U., Brinkmann Frye E., Degenhardt T.P., Thorpe S.R., Baynes J.W. (1997). Nε-(Carboxyethyl)lysine, a product of chemical modification of proteins by methylglyoxal, increases with age in human lens proteins. Biochem J 324: 565-570.
3. Ahmed N., Ahmed U., Thornalley P.J., Hager K., Fleischer G.A., Munch G. (2004a). Protein glycation, oxidation and nitration marker residues and free adducts of cerebrospinal fluid in Alzheimer's disease and link to cognitive impairment. J Neurochem 92: 255-263.
4. Ahmed N., Argirov O.K., Minhas H.S., Cordeiro C.A., Thornalley P.J. (2002). Assay of advanced glycation endproducts (AGEs): Surveying AGEs by chromatographic assay with derivatisation by aminoquinolyl-N-hydroxysuccimidyl-carbamate and application to Nε-carboxymethyl-lysine-and Nε-(1-carboxyethyl)lysine-modified albumin. Biochem J 364: 1-14.
5. Ahmed N., Babaei-Jadidi R., Howell S.K., Beisswenger P.J., Thornalley P.J. (2005a). Degradation products of proteins damaged by glycation, oxidation and nitration in clinical type 1 diabetes. Diabetologia 48: 1590-1603.
6. Ahmed N., Dobler D., Dean M., Thornalley P.J. (2005b). Peptide mapping identifies hotspot site of modification in human serum albumin by methylglyoxal involved in ligand binding and esterase activity. J Biol Chem 280: 5724-5732.
7. Ahmed N., Mirshekar-Syahkal B., Kennish L., Karachalias N., Babaei-Jadidi R., Thornalley P.J. (2005c). Assay of advanced glycation endproducts in selected beverages and food by liquid chromatography with tandem mass spectrometric detection. Molec Nutrit Food Res 49: 691-699.
8. Ahmed N., Thornalley P.J. (2002). Chromatographic assay of glycation adducts in human serum albumin glycated in vitro by derivatisation with aminoquinolyl-N-hydroxysuccimidyl-carbamate and intrinsic fluorescence. Biochem J 364: 15-24.
9. Ahmed N., Thornalley P.J., Dawczynski J., Franke S., Strobel J., Stein G., Haik G.M. Jr. (2003). Methylglyoxal-derived hydroimidazolone advanced glycation endproducts of human lens proteins. Invest Ophthalmol Vis Sci 44: 5287-5292.
10. Ahmed N., Thornalley P.J., Luthen R., Haussinger D., Sebekova K., Schinzel R., Voelker W., Heidland A. (2004b). Processing of protein glycation, oxidation and nitrosation adducts in the liver and the effect of cirrhosis. J Hepatol 41: 913-919.
11. Babaei-Jadidi R., Karachalias N., Ahmed N., Battah S., Thornalley P.J. (2003). Prevention of incipient diabetic nephropathy by high dose thiamine and Benfotiamine. Diabetes 52: 2110-2120.
12. Babaei-Jadidi R., Karachalias N., Kupich C., Ahmed N., Thornalley P.J. (2004). High dose thiamine therapy counters dyslipidaemia in streptozotocin-induced diabetic rats. Diabetologia 47: 2235-2246.
13. Baptista J.A.B., Carvalho R.C.B. (2004). Indirect determination of Amadori compounds in milk-based products by HPLC/ELSD/UV as an index of protein deterioration. Food Res Internat 37: 739-747.
14. Bar K.J., Franke S., Wenda B., Muller S., Kientsch-Engel R., Stein G., Sauer H. (2003). Pentosidine and N-epsilon-(carboxymethyl)-lysine in Alzheimer's disease and vascular dementia. Neurobiol Aging 24: 333-338.
15. Bergmann R., Helling R., Heichert C., Scheunemann W., Mading P., Wittrisch H., Johannsen B., Henle T. (2001). Radiofluorination and positron emission tomography (PET) as a new approach to study the in vivo distribution and elimination of the advanced glycation endproducts Nε-carboxymethyllysine (CML) and Nε-carboxyethyllysine (CEL). Nahrung-Food 45: 182-188.
16. Berlett B.S., Stadtman E.R. (1997). Protein oxidation in aging, disease and oxidative stress. J Biol Chem 272: 20313-20316.
17. Bianchi G., Marchesini G., Fabbri A., Ronchi M., Chianese R., Grossi G. (1997). Lipoperoxide plasma levels in patients with liver cirrhosis. Hepato-Gastroenterology 44: 784-788.
18. Biemel K.M., Buhler H.P., Reihl O., Lederer M.O. (2001). Identification and quantitative evaluation of the lysine-arginine crosslinks GODIC, MODIC, DODIC, and glucosepan in foods. Nahrung-Food 45: 210-214.
19. Biemel K.M., Friedl D.A., Lederer M.O. (2002). Identification and quantification of major Maillard cross-links in human serum albumin and lens protein-Evidence for glucosepane as the dominant compound. J Biol Chem 277: 24907-24915.
20. Birlouez-Aragon I., Pischetsrieder M., Leclere J., Morales F.J., Hasenkopf K., Kientsch-Engel R., Ducauze C.J., Rutledge D. (2004). Assessment of protein glycation markers in infant formulas. Food Chem 87: 253-259.
21. Blennow K. (2004a). Cerebrospinal fluid markers for Alzheimer's disease. NeuroRx 1: 213-225.
22. Blennow K. (2004b). CSF markers for mild cognitive impairment. J Intern Med 256: 224-234.
23. Bossy-Wetzel E., Schwarzenbacher R., Lipton S.A. (2004). Molecular pathways to neurodegeneration. Nat Med 10: S2-S9.
24. Brot N., Weissbach H. (1983). Biochemistry and physiological role of methionine sulfoxide reductase in proteins. Arch Biochem Biophys 253: 271-281.
25. Brownlee M. (2001). Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820.
26. Burroughs A., McNamara D. (2003). Liver disease in Europe. Alimentary Pharmacol Therapeut 18: 54-59.
27. Cai W., He J.C., Zhu L., Peppa M., Lu C., Uribarri J., Vlassara H. (2004). High levels of dietary advanced glycation end products transform low-density lipoprotein into a potent redox-sensitive mitogen-activated protein kinase stimulant in diabetic patients. Circulation 110: 285-291.
28. Cai W.J., Gao Q.D., Zhu L., Peppa M., He C.J., Vlassara H. (2002). Oxidative stressinducing carbonyl compounds from common foods: Novel mediators of cellular dysfunction. Mol Med 8: 337-346.
29. Calabrese V., Scapagnini G., Ravagna A., Bella R., Foresti R., Bates T.E., Stella A.M.G., Pennisi G. (2002). Nitric oxide synthase is present in the cerebrospinal fluid of patients with active multiple sclerosis and is associated with increases in cerebrospinal fluid protein nitrotyrosine and S-nitrosothiols and with changes in glutathione levels. J Neurosci Res 70: 580-587.
30. Casserly I., Topol E. (2004). Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. Lancet 363: 1139-1146.
31. Castegna A., Thongboonkerd V., Klein J.B., Lynn B., Markesbery W.R., Butterfield D.A. (2003). Proteomic identification of nitrated proteins in Alzheimer's disease brain. J Neurochem 85: 1394-1401.
32. Ceriello A., Quagliaro L., Catone B., Pascon R., Piazzola M., Bais B., Marra G., Tonutti L., Taboga C., Motz E. (2002). Role of hyperglycemia in nitrotyrosine postprandial generation. Diabetes Care 25: 1439-1443.
33. Ceriello A., Quagliaro L., Piconi L., Assaloni R., Da Ros R., Maier A., Esposito K., Giugliano D. (2004). Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. Diabetes 53: 701-710.
34. Chen F., Wollmer M.A., Hoerndli F., Munch G., Kuhla B., Rogaev E.I., Tsolaki M., Papassotiropoulos A., Gotz J. (2004). Role for glyoxalase I in Alzheimer's disease. Proc Natl Acad Sci USA 101: 7687-7692.
35. Chuyen N.V. (2001). Maillard reaction and food processing. Application aspects. In: Shahidi S. (ed.), Process-Induced Chemical Changes in Food, Plenum Press, New York, pp. 213-235.
36. Cross A.H., Manning P.T., Keeling R.M., Schmidt R.E., Misko T.P. (1998). Peroxynitrite formation within the central nervous system in active multiple sclerosis. J Neuroimmunol 88: 45-56.
37. Cumming R.C., Andon N.L., Haynes P.A., Park M., Fischer W.H., Schubert D. (2004). Protein disulfide bond formation in the cytoplasm during oxidative stress. J Biol Chem 279: 21749-21758.
38. Degenhardt T.P., Thorpe S.R., Baynes J.W. (1998). Chemical modification of proteins by methylglyoxal. Cell Molec Biol 44: 1139-1145.
39. DeGroot J., Verzijl N.,Wenting-VanWijk M.J.G., Bank R.A., Lafeber F.P.J.G., Bijlsma J. W.J., TeKoppele J.M. (2001). Age-related decrease in susceptibility of human articular cartilage to matrix metalloproteinase-mediated degradation-The role of advanced glycation end products. Arthritis Rheum 44: 2562-2571.
40. Delpierre G., Vertommen D., Communi D., Rider M.H., Van Schaftingen E. (2004). Identification of fructosamine residues deglycated by fructosamine-3-kinase in human hemoglobin. J Biol Chem 279: 27613-27620.
41. Denu J.M., Tanner K.G. (1998). Specific and reversible inactivation of protein tyrosine phosphatases by hydrogen peroxide: Evidence for a sulfenic acid intermediate and implications for redox regulation. Biochemistry 37: 5633-5642.
42. Deuther-Conrad W., Franke S., Sommer M., Henle T., Stein G. (2001). Differences in the modulating potential of advanced glycation (AGE) peptides versus AGE proteins. Kidney Internat 59: S63-S66.
43. Dobler D., Ahmed N., Thornalley P.J. (2004) Peptide mapping of type IV collagen modified minimally by methylglyoxal in vitro. Ann N Y Acad Sci 1043: 906.
44. Dragsted L.O., Daneshvar B., Vogel U., Autrup H.N., Wallin H., Risom L., Moller P., Molck A.M., Hansen M., Poulsen H.E., Loft S. (2002). A sucrose-rich diet induces mutations in the rat colon. Cancer Res 62: 4339-4345.
45. Du X., Matsumura T., Edelstein D., Rosetti L., Zsengeller Z., Szabo C., Brownlee M. (2003). Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest 112: 1049-1057.
46. Du X., Stockklauser-Farber K., Rosen P. (1999). Generation of reactive oxygen intermediates, activation of NF-kB and induction of apoptosis in human endothelial cells by glucose: Role of nitric oxide synthase? Free Radic Biol Med 27: 752-763.
47. Eiserich J.P., Hristova M., Cross C.E., Jones A.D., Freeman B.A., Halliwell B., van der Vliet A. (1998). Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils. Nature 391: 393-397.
48. Faist V., Erbersdobler H. (2001). Metabolic transit and in vivo effects of melanoidins and precursor compounds deriving from the Maillard reaction. Ann Nutr Met 45: 1-12.
49. Fataccioli V., Andraud E., French S.W., Rouach H. (1999). Effects of chronic ethanol administration on rat liver proteasome activities: relationship with oxidative stress. Hepatology 29: 14-20.
50. Foerster A., Henle T. (2003). Glycation in food and metabolic transit of dietary AGEs (advanced glycation end-products): Studies on the urinary excretion of pyrraline. Biochem Soc Trans 31: 1383-1385.
51. Friedlander M.A., Wu Y.W., Elgawish A., Monnier V.M. (1996). Early and advanced glycosylation end products: Kinetics of formation and clearance in peritoneal dialysis. J Clin Invest 97: 728-735.
52. Fukunaga Y., Katsuragi Y., Izumi T., Sakiyama F. (1982). Fluorescence characteristics of kynurenine and N′-formylkynurenine: Their use as reporters of the environment of tryptophan 62 in hen egg-white lysozyme. J Biochem 92: 129-141.
53. Gabris J., Duran A. (1983). Level of free amino-acids in the milk of cows in relation to their levels in arterial and venous blood. Vet Med 28: 465-471.
54. Gallet X., Charloteaux B., Thomas A., Braseur R. (2000). A fast method to predict protein interaction sites from sequences. J Mol Biol 302: 917-926.
55. Gaut J.P., Byun J., Tran H.D., Heinecke J.W. (2002). Artifact-free quantitation of free 3-chlorotyrosine, 3-bromotyrosine, and 3-nitrotyrosine in human plasma by electron capture-negative chemical ionization gas chromatography mass spectrometry and liquid chromatography-electrospray ionization tandem mass spectrometry. Anal Biochem 300: 252-259.
56. Geibauf A., van Wickern B., Simat T., Steinhart H., Esterbauer H. (1996). Formation of N-formylkynurenine suggests the involvement of apolipoprotein B-100 centered tryptophan radicals in the initiation of LDL lipid peroxidation. FEBS Lett 389: 136-140.
57. Gerner C., Vejda S., Gelbmann D., Bayer E., Gotzmann J., Schulte-Hermann R., Mikulitis W. (2002). Concomitant determination of absolute values of cellular protein amounts, synthesis rates, and turnover rates by quantitative proteome profiling. Mol Cell Proteomics 1: 528-537.
58. Giulivi C., Davies K.J.A. (2001). Mechanism of the formation and proteolytic release of H2O2-induced dityrosine and tyrosine oxidation products in hemoglobin and red blood cells. J Biol Chem 276: 24129-24136.
59. Gladwin M.T., Lancaster J.R., Freeman B.A., Schechter A.N. (2003). Nitric oxide's reactions with hemoglobin: A view through the SNO-storm. Nat Med 9: 496-500.
60. Goldberg A.L. (2003). Protein degradation and protection against misfolded or damaged proteins. Nature 426: 895-899.
61. Goldberg T., Cai W.J., Peppa M., Dardaine V., Baliga B.S., Uribarri J., Vlassara H. (2004). Advanced glycoxidation end products in commonly consumed foods. J Am Dietetic Assoc 104: 1287-1291.
62. Good P.F., Hsu A.,Werner P., Perl D.P., Olanow C.W. (1998). Protein nitration in Parkinson's disease. J Neuropathol Exp Neurol 57: 338-342.
63. Good P.F., Werner P., Hsu A., Olanow C.W., Perl D.P. (1996). Evidence for neuronal oxidative damage in Alzheimer's disease. Am J Pathol 149: 21-28.
64. Greive K.A., Balazs N.D.H., Comper W.D. (2001). Protein fragments in urine have been considerably underestimated by various protein assays. Clin Chem 47: 1717-1719.
65. Haik JR G.M., Lo T.W.C., Thornalley P.J. (1994). Methylglyoxal concentration and glyoxalase activities in human lens. Exp Eye Res 59: 497-500.
66. Hammes H.-P., Du X., Edelstein D., Taguchi T., Matsumura T., Ju Q., Lin J., Bierhaus A., Nawroth P., Hannak D., Neumaier M., Bergfeld R., Giardino I., Brownlee M. (2003). Benfotiamine blocks threemajor pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 9: 294-299.
67. Hassan R., Qureshi H., Zuberi S.J. (1991). Effect of thiamine on glucose-utilization in hepatic cirrhosis. J Gastroenterol Hepatol 6: 59-60.
68. Hayashi T., Shibamoto T. (1985). Analysis of methylglyoxal in foods and beverages. J Agric Food Chem 33: 1090-1093.
69. Hayes J.D., Flanagan J.U., Jowsey I.R. (2005). Glutathione transferases. Ann Rev Pharmacol Toxicol 45: 51-88.
70. He C., Sabol J., Mitsuhashi T., Vlassara H. (1999). Dietary glycotoxins. Inhibition of reactive products by aminoguanidine facilitates renal clearance and reduced tissue sequestration. Diabetes 48: 1308-1315.
71. Henle T. (2003). AGEs in foods: Do they play a role in uremia? Kidney Int 63: S145-S147.
72. Henle T., Walter A., Haeβner R., Klostermeyer H. (1994). Detection and identification of a protein-bound imidazolone resulting from the reaction of arginine residues and methylglyoxal. Z Lebensm Unters Forsch 199: 55-58.
73. Henle T.,Walter H., Klostermeyer H. (1991). Evaluation of the extent of the early Maillardreaction in milk products by direct measurement of the Amadori-product lactuloselysine. Z Lebensm Unters Forsch 193: 119-122.
74. Hensley K., Maidt M.L., Yu Z., Sang H., Markesbery W.R., Floyd R.A. (1998). Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation. J Neurosci 18: 8126-8132.
75. Hink U., Li H., Mollnau H., Oelze M., Matheis E., Hartmann M., Skatchkov M., Thaiss F., Stahl R.A.K., Warnholtz A., Meinertz T., Griendling K., Harison D.G., Fostermann U., Munzel T. (2001). Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 88: 14-22.
76. Honda K., Nitta K., Horita S., Yumura W., Nihei H., Nagai R., Ikeda K., Horiuchi S. (1999). Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration. Nephrol Dialysis Transplant 14: 1541-1549.
77. Hurst J.K. (2002). Whence nitrotyrosine. J Clin Invest 109: 1287-1289.
78. Hutin Y., Kitler M.E., Dore G.J., Perz J.F., Armstrong G.L., Dusheiko G., Ishibashi H., Grob P., Kew M., Marcellin P., Seeff L.B., Beutels P., Nelson C., Stein C., Zurn P., Clifford G., Vranckx R., Alberti A., Hallaj Z.S., Hadler S., Lavanchy D. (2004). Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 44: 20-29.
79. Iberg N., Fluckiger R. (2002). Nonenzymatic glycosylation of albumin in vivo: Identification of multiple glycosylation sites. J Biol Chem 261: 13542-13545.
80. Ikeda K., Higashi T., Sano H., Jinnouchi Y., Yishida M., Araki T., Ueda S., Horiuchi S. (1996). Nε-(Carboxymethyl)lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction. Biochemistry 35: 8075-8083.
81. Ishii T., Itoh K., Ruiz E., Leake D.S., Unoki H., Yamamoto M., Mann G.E. (2004). Role of Nrf2 in the regulation of CD36 and stress protein expression in murine macrophages: activation by oxidatively modified LDL and 4-hydroxynonenal. Circ Res 94: 609-616.
82. Jennings P.E., McLaren M., Scott N.A., Saniabadi A.R., Belch J.J.F. (1991). The relationship of oxidative stress to thrombotic tendency in type-1 diabetic patients with retinopathy. Diabetic Medicine 8: 860-865.
83. Johnson R.N., Easdale R.W., Tatnell M., Baker J.R. (1991). Significance of variation in turnover of glycated albumin on indexes of diabetic control. Clin Chim Acta 198: 229-238.
84. Kharbanda K.K., Todero S.L., Shubert K.A., Sorrell M.F., Tuma D.J. (2001). Malondialdehyde-acetaldehyde-protein adducts increase secretion of chemokines by rat hepatic stellate cells. Alcohol 25: 123-128.
85. Koito W., Araki T., Horiuchi S., Nagai R. (2004). Conventional antibody against Nε-(carboxymethyl)lysine (CML) shows cross-reaction to Nε-(carboxyethyl)lysine (CEL): Immunochemical quantification of CML with a specific antibody. J Biochem 136: 831-837.
86. Koo J.R., Vaziri N.D. (2003). Effects of diabetes, insulin and antioxidants on NO synthase abundance and NO interaction with reactive oxygen species. Kidney Int 63: 195-201.
87. Koschinsky T., He C.-J., Mitsuhashi T., Bucala R., Liu C., Buenting C., Heitman K., Vlassara H. (1997). Orally absorbed reactive glycation products (glycotoxins): An environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci USA 94: 6474-6479.
88. Kukull W., Larson E., Teri L., Bowen J., McCormick W., Pfanschmidt M.L. (1994). The Mini-Mental State Examination score and the clinical diagnosis. J Clin Epidemiol 47: 1061-1067.
89. Kuzuya M., Asai T., Kanda S., Maeda K., Cheng X.W., Iguchi A. (2001). Glycation crosslinks inhibit matrix metalloproteinase-2 activation in vascular smooth muscle cells cultured on collagen lattice. Diabetologia 44: 436.
90. Lapolla A., Tubaro M., Reitano R., Arico N.C., Ragazzi E., Seraglia R., Vogliardi S., Traldi P., Fedele D. (2004). The complexity of non-enzymatic glycation product sets of human globins. Diabetologia 47: 1712-1715.
91. Lavanchy D. (2004). Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepatitis 11: 97-107.
92. Le Moine O., Evrard S., Eisendrath P., Descamps C., Deviere J. (2000). Treatment of alcoholic hepatitis with intravenous n-acetylcysteine (NAC): A pilot trial. Gastroenterology 118: 1069.
93. Leeuwenburgh C., Hansen P.A., Holloszy J.O., Heinecke J.W. (1999). Oxidized amino acids in the urine of aging rats: Potential markers for assessing oxidative stress in vivo. Am J Physiol-Regulatory Integrative and Comparative Physiol 276: R128-R135.
94. Levy S., Herve C., Delacoux E., Erlinger S. (2002). Thiamine deficiency in hepatitis C virus and alcohol-related liver diseases. Digestive Dis and Sci 47: 543-548.
95. Liardon R., de Weck-Gaudard D., Philipossian G., Finot P.-A. (1987). Identification of Nε-carboxymethyllysine: A new Maillard reaction product, in rat urine. J Agric Food Chem 35: 427-431.
96. Luth H.J., Munch G., Arendt T. (2002). Aberrant expression of NOS isoforms in Alzheimer's disease is structurally related to nitrotyrosine formation. Brain Res 953: 135-143.
97. Makita Z., Radoff S., Rayfield E.J., Friedman E.A., Kaufman A.M., Korbet S.M., Barth R.H., Winston J.A., Fuh H., Manogue K.R., Cerami A., Vlassara H. (1994). Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet 343: 1519-1522.
98. Mattson M.P. (2004). Pathways towards and away from Alzheimer's disease. Nature 430: 631-639.
99. Mavric E., Kumpf Y., Schuster K., Kappenstein O., Scheller D., Henle T. (2004). A new imidazolinone resulting from the reaction of peptide-bound arginine and oligosacccharides with 1,4-glycosidic linkages. Eur Food Res Technol 218: 213-218.
100. May C., Kaye J.A., Atack J.R., Schapiro M.B., Friedland R.P., Rapoport S.I. (1990). Cerebrospinal fluid production is reduced in healthy aging. Neurology 40: 500-503.
101. McCance D.R., Dyer D.G., Dunn J.A., Baiue K.E., Thorpe S.R., Baynes J.W., Lyons T.J. (1993). Maillard reaction products and their relation to complications in insulindependent diabetes mellitus. J Clin Invest 91: 2470-2478.
102. McLellan A.C., Thornalley P.J., Benn J., Sonksen P.H. (1994). The glyoxalase system in clinical diabetes mellitus and correlation with diabetic complications. Clin Sci 87: 21-29.
103. Mortier S., Faict D., Schalkwijk C.G., Lameire N.H., De Vriese A.S. (2004). Long-term exposure to new peritoneal dialysis solutions: Effects on the peritoneal membrane. Kidney Int 66: 1257-1265.
104. Mottaran E., Stewart S.F., Rolla R., Vay D., Cipriani V., Moretti M., Vidali M., Sartori M., Rigamonti C., Day C.P., Albano E. (2002). Lipid peroxidation contributes to immune reactions associated with alcoholic liver disease. Free Radic Biol Med 32: 38-45.
105. Murray J., Taylor S.W., Zhang B., Ghosh S.S., Capaldi R.A. (2003). Oxidative damage to mitochondrial complex I due to peroxynitrite. J Biol Chem 278: 37223-37230.
106. Myint T., Hoshi S., Ookawara T., Miyazawa N., Keiichiro M., Suzuki K., Taniguchi N. (1995). Immunological detection of glycated proteins in normal and streptozotocininduced diabetic rats using anti hexitol-lysine IgG. Biochim Biophys Acta 1272: 73-79.
107. Nagai R., Unno Y., Hayashi M.C., Masuda S., Hayase F., Kinae N., Horiuchi S. (2002). Increased 3-NT dityrosine residues in post-mortem brain tissue was found in several neurological disorders including Parkinson's disease, multiple sclerosis and amyotrophic lateral sclerosis of Amadori product and generation of glucosone and glyoxal from glucose. Diabetes 51: 2833-2839.
108. Nagao M., Fujita Y., Sugimura T., Kosuge T. (1986). Methylglyoxal in beverages and foods its mutagenicity and carcinogenicity. IARC Sci Publ 70: 283-291.
109. Nakamura S., Miyazaki S., Sakai S., Morita T., Hirasawa Y., Niwa T. (2001). Localization of imidazolone in the peritoneum of CAPD patients: A factor for a loss of ultrafiltration. Am J Kidney Dis 38: S107-S110.
110. Nestor P.J., Scheltens P., Hodges J.R. (2004). Advances in the early detection of Alzheimer's disease. Nat Med 10: S34-S41.
111. Nishikawa T., Edelstein D., Liang Du X., Yamagishi S., Matsumura T., Kaneda Y., Yorek M.A., Beede D., Oates P.J., Hammes H.-P., Giardino I., Brownlee M. (2000). Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemia damage. Nature 404: 787-790.
112. Niwa T. (1999). 3-Deoxyglucosone: Metabolism, analysis, biological activity, and clinical implication. J Chromatogr B 731: 23-36.
113. Ohshima H., Friesen M., Brouet I., Bartsch H. (1990). Nitrotyrosine as a new marker for endogenous nitrosation and nitration of proteins. Food Chem Toxicol 28: 647-652.
114. Oste R.E., Miller R., Sjostrom H., Noren O. (1987). Effect of Maillard reaction-products on protein digestion-Studies on pure compounds. J Agric Food Chem 35: 938-942.
115. Owen W.F., Lew N.L., Liu Y., Lowrie E.G., Lazarus J.M. (1993). The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. New Engl J Med 329: 1001-1006.
116. Paradis V., Kollinger M., Fabre M., Holstege A., Poynard T., Bedossa P. (1997). In situ detection of lipid peroxidation by-products in chronic liver diseases. Hepatology 26: 135-142.
117. Petrides A.S., Vogt C., Schulzeberge D., Matthews D., Strohmeyer G. (1994). Pathogenesis of glucose-intolerance and diabetes-mellitus in cirrhosis. Hepatology 19: 616-627.
118. Piraud M., Vianey-Saban C., Petritis K., Elfakir C., Steghens J.P., Morla A., Bouchu D. (2003). ESI-MS/MS analysis of underivatised amino acids: A new tool for the diagnosis of inherited disorders of amino acid metabolism. Fragmentation study of 79 molecules of biological interest in positive and negative ionisation mode. Rapid Commun Mass Spectrom 17: 1297-1311.
119. Pouletty P. (2002). Drug addictions: Towards socially accepted and medically treatable diseases. Nat Rev Drug Discov 1: 731-736.
120. Predescu D., Predescu S., Malik A.B. (2002). Transport of nitrated albumin across continuous vascular endothelium. Proc Natl Acad Sci USA 99: 13932-13937.
121. Pryor W.A., Jin X., Squadrito G.L. (1994). One electron and two electron oxidations of methionine by peroxynitrite. Proc Natl Acad Sci USA 91: 11173-11177.
122. Quijano C., Alvarez B., Gatt R.M., Augusto O., Radi R. (1997). Pathways of peroxynitrite oxidation of thiol groups. Biochem J 322: 167-173.
123. Rahman T.M. Hodgson H.J.F. (2003). The effects of early and late administration of inhibitors of inducible nitric oxide synthase in a thioacetamide-induced model of acute hepatic failure in the rat. J Hepatology 35: 583-590.
124. Rashed M.S., Ozand P.T., Bucknall M.P., Little D. (1995). Diagnosis of inborn-errors of metabolism from blood spots by acylcarnitines and amino-acids profiling using automated electrospray tandem mass-spectrometry. Pediatric Res 38: 324-331.
125. Reiter C.D., Teng R.J., Beckman J.S. (2000). Superoxide reacts with nitric oxide to nitrate tyrosine at physiological pH via peroxynitrite. J Biol Chem 275: 32460-32466.
126. Roberts N.B., Amara A.B., Morris M., Green B.N. (2001). Long-term evaluation of electrospray ionization mass spectrometric analysis of glycated hemoglobin. Clin Chem 47: 316-321.
127. Russo L.M., Bakris G.L., Comper W.D. (2002). Renal handling of albumin: A critical review of basic concepts and perspective. Am J Kidney Dis 39: 899-919.
128. Ryberg H., Soderling A.S., Davidsson P., Blennow K., Caidahl K., Persson L.I. (2004). Cerebrospinal fluid levels of free 3-nitrotyrosine are not elevated in the majority of patients with amyotrophic lateral sclerosis or Alzheimer's disease. Neurochem Internat 45: 57-62.
129. Sacks D.B., Bruns D.E., Goldstein D.E., Maclaren N.K., McDonald J.M., Parrott M. (2002). Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 48: 436-472.
130. Sasaki S., Shibata N., Komori T., Iwata M. (2000). iNOS and nitrotyrosine immunoreactivity in amyotrophic lateral sclerosis. Neurosci Lett 291: 44-48.
131. Scaloni A., Perillo V., Franco P., Fedele E., Froio R., Ferrara L., Bergamo P. (2002). Characterization of heat-induced lactosylation products in caseins by immunoenzymatic and mass spectrometric methodologies. Biochim Biophys Acta-Proteins and Proteomics 1598: 30-39.
132. Schleicher E.D., Wagner E., Nerlich A.G. (1997). Increased accumulation of the glycoxidation product Nε-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest 99: 457-468.
133. Schwemmer M., Fink B., Kockerbauer R., Bassenge E. (2000). How urine analysis reflects oxidative stress-Nitrotyrosine as a potential marker. Clin Chim Acta 297: 207-216.
134. Sebekova K., Kupcova V., Schinzel R., Heidland A. (2002). Markedly elevated levels of plasma advanced glycation end products in patients with liver cirrhosis-Amelioration by liver transplantation. J Hepatology 36: 66-71.
135. Sebekova K., Podracka L., Blazicek P., Syrova D., Heidland A., Schinzel R. (2001). Plasma levels of advanced glycation end products in children with renal disease. Pediatric Nephrol 16: 1105-1112.
136. Shuvaev V.V., Laffont I., Serot J.-M., Fujii J., Taniguchi N., Siest G. (2001). Increased protein glycation in cerebrospinal fluid of Alzheimer's disease. Neurobiol Aging 22: 397-402.
137. Silverberg G.D., Heit G., Huhn S., Jaffe R.A., Chang S.D., Bronte-Stewart H., Rubenstein E., Possin K., Saul T.A. (2001). The cerebrospinal fluid production rate is reduced in dementia of the Alzheimer's type. Neurology 57: 1763-1766.
138. Sitte N., Merker K., von Zglinicki T., Davies K.J.A., Grune T. (2000). Protein oxidation and degradation during cellular senescence of human BJ fibroblasts. Part II: Aging of non-dividing cells. FASEB J 14: 2503-2510.
139. Smith M.A., Perry G., Sayre L.M., Anderson V.E., Beal M.F., Kowall N. (1996). Oxidative damage in Alzheimer's disease. Nature 382: 120-121.
140. Smith M.A., Richey Harris P.L., Sayre L.M., Beckman J.S., Perry G. (1997). Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci 17: 2653-2657.
141. Smith M.A., Taneda S., Richey P.L., Miyata S., Yan S.-D., Stern D., Sayre L.M., Monnier V.M., Perry G. (1994). Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc Natl Acad Sci USA 91: 5710-5714.
142. Soriano F.G., Virag L., Jagtap P., Szabo E., Mabley J.G., Liaudet L., Marton M., Hoyt D.G., Murthy K.G.K., Salzman A.L., Southan G.J., Szabo C. (2001). Diabetic endothelial dysfunction: The role of poly(ADP-ribose) polymerase activation. Nat Med 7: 108-113.
143. Sterling K. (1951). Serum albumin turnover in Laennec's cirrhosis as measured by 131Itagged albumin. J Clin Invest 30: 1238-1246.
144. Stratton I.M., Adler A.I., Neil H.A.W., Matthews D.R., Manley S.E., Cull C.A., Hadden D., Turner R.C., Holman R.R. (2002). Association of glycaemic with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321: 405-412.
145. Szwergold B.S., Howell S., Beisswenger P.J. (2001). Human fructosamine-3-kinase. Purification, sequencing, substrate specificity, and evidence of activity in vivo. Diabetes 50: 2139-2147.
146. Terelius Y., Norsten-Hoog C., Cronholm T., Ingelman-Sundberg M. (2003). Acetaldehyde as a substrate for ethanol-inducible cytochrome P450 (CYP2E1). Biochem Biophys Res Commun 179: 689-694.
147. The Diabetes Control and Complications Trial Research Group (1993). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med 327: 977-986.
148. Thornalley P.J. (1988). Modification of the glyoxalase system in human red blood cells by glucose in vitro. Biochem J 254: 751-755.
149. Thornalley P.J. (1998). Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. Cell Mol Biol 44: 1013-1023.
150. Thornalley P.J. (1999). Clinical significance of glycation. Clin Lab 45: 263-273.
151. Thornalley P.J. (2003a). Glyoxalase I-Structure, function and a critical role in the enzymatic defence against glycation. Biochem Soc Trans 31: 1343-1348.
152. Thornalley P.J. (2003b). The enzymatic defence against glycation in health, disease and therapeutics: a symposium to examine the concept. Biochem Soc Trans 31: 1343-1348.
153. Thornalley P.J. (2003c). Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch Biochem Biophys 419: 31-40.
154. Thornalley P.J. (2004). Glycation, receptor-mediated cell activation and vascular complications of diabetes. Diabetes Vac Dis Res 1: 21-22.
155. Thornalley P.J. (2005) Dicarbonyl intermediates in the Maillard reaction. Ann NY Acad Sci 1043: 111-117.
156. Thornalley P.J., Argirova M., Ahmed N., Mann V.M., Argirov O.K., Dawnay A. (2000a). Mass spectrometric monitoring of albumin in uraemia. Kidney Internat 58: 2228-2234.
157. Thornalley P.J., Battah S., Ahmed N., Karachalias N., Agalou S., Babaei-Jadidi R., Dawnay A. (2003). Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochem J 375: 581-592.
158. Thornalley P.J., Langborg A., Minhas H.S. (1999). Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 344: 109-116.
159. Thornalley P.J., Yurek-George A., Argirov O.K. (2000b). Kinetics and mechanism of the reaction of aminoguanidine with the α-oxoaldehydes, glyoxal, methylglyoxal and 3-deoxyglucosone under physiological conditions. Biochem Pharmacol 60: 55-65.
160. Tohgi H., Abe T., Yamazaki K., Murata T., Ishizaki E., Isobe C. (1999). Alterations of 3-nitrotyrosine concentration in the cerebrospinal fluid during aging and in patients with Alzheimer's disease. Neurosci Lett 269: 52-54.
161. Ueno H., Segawa T., Hasegawa T., Nakamuro K., Maeda H. (1991). Subchronic oral toxicity of glyoxal via drinking water in rats. Fundam Appl Toxicol 16: 763-772.
162. Uribarri J., Peppa M., Cai W.J., Goldberg T., Lu M., Baliga S., Vassalotti J.A., Vlassara H. (2003). Dietary glycotoxins correlate with circulating advanced glycation end product levels in renal failure patients. Am J Kidney Dis 42: 532-538.
163. Verdier Y. Penke B. (2004). Binding sites of amyloid beta-peptide in cell plasma membrane and implications for Alzheimer's disease. Curr Protein Peptide Sci 5: 19-31.
164. Verzijl N., DeGroot J., Thorpe S.R., Bank R.A., Shaw J.N., Lyons T.J., Bijlsma J.W.J., Lafeberi F.P.J.G., Baynes J.W., TeKoppele J.M. (2000). Effect of collagen turnover on the accumulation of advanced glycation endproducts. J Biol Chem 275: 39027-39031.
165. Vlassara H., Cai W.J., Crandall J., Goldberg T., Oberstein R., Dardaine V., Peppa M., Rayfield E.J. (2002). Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci USA 99: 15596-15601.
166. Weissbach H., Etienne F., Hoshi T., Heinemann S.H., Lowther W.T., Matthews B., St John G., Nathan C., Brot N. (2002). Peptide methionine sulfoxide reductase: Structure, mechanism of action, and biological function. Arch Biochem Biophys 397: 172-178.
167. Wells-Knecht M.C., Lyons T.J., McCance D.R., Thorpe S.R., Baynes J.W. (1997). Agedependent increases in ortho-tyrosine and methionine sulfoxide in human skin collagen is not accelerated in diabetes. J Clin Invest 100: 839-846.
168. Wenzel E., Tasto S., Erbersdobler H.F., Faist V. (2002). Effect of heat-treated proteins on selected parameters of the biotransformation system in the rat. Ann Nutrit Metab 46: 9-16.
169. Willis M.S., Klassen L.W., Tuma D.J., Thiele G.M. (2002). Malondialdehyde-acetaldehyde-haptenated protein Induces cell death by induction of necrosis and apoptosis in immune cells. Internat Immunopharmacol 2: 519-535.
170. Wynne A., Sauter C., Gibson G.R., Ames J.M. (2002). Microbial degradation of heated gluten-glucose systems and the implications for human gut health. Maillard Reaction in Food Chemistry and Medical Science: Update for the Postgenomic Era 1245: 481-482.
171. Yoshihara K., Okumura T., Yoshida T., Beppu M. (2001). Inhibitory effect of peptidefree forms of advanced glycation end products on the proliferation and extracellular matrix protein production of cultured cells. J Health Sci 47: 296-301.
172. Zhang X., Medzihradszhy K.F., Cunningham J., Lee P.D.K., Rognerud C.L., Ou C.-N., Harmatz P., Witkowska H.E. (2001). Characterization of glycated hemoglobin in diabetic patients: usefulness of electrospray mass spectrometry in monitoring the extent and distribution of glycation. J Chromatogr B 759: 1-15.
173. Zhang X.M., Chan C.C., Stamp D., Minkin S., Archer M.C., Bruce W.R. (1993). Initiation and promotion of colonic aberrant crypt foci in rats by 5-hydroxymethyl-2-furaldehyde in thermolyzed sucrose. Carcinogenesis 14: 773-775.
174. Zill H., Bek S., Hofmann. T., Huber J., Frank O., Lindenmeier M., Weigle B., Erbersdobler H.F., Scheidler S., Busch A.E., Faist V. (2003). RAGE-mediated MAPK activation by food-derived AGE and non-AGE products. Biochem Biophys Res Commun 300: 311-313.